IN2014MN01672A - - Google Patents
Info
- Publication number
- IN2014MN01672A IN2014MN01672A IN1672MUN2014A IN2014MN01672A IN 2014MN01672 A IN2014MN01672 A IN 2014MN01672A IN 1672MUN2014 A IN1672MUN2014 A IN 1672MUN2014A IN 2014MN01672 A IN2014MN01672 A IN 2014MN01672A
- Authority
- IN
- India
- Prior art keywords
- casr
- lessening
- syndromes
- severity
- modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides calcium sensing receptor modulators (CaSR). In particular the compounds described herein are useful for treating managing and/or lessening the severity of diseases disorders syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof and methods for treating managing and/or lessening the severity of diseases disorders syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1672MUN2014 IN2014MN01672A (en) | 2012-02-24 | 2013-02-22 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN178KO2012 | 2012-02-24 | ||
| IN1030KO2012 | 2012-09-07 | ||
| PCT/IB2013/051445 WO2013124828A1 (en) | 2012-02-24 | 2013-02-22 | Substituted chroman compounds as calcium sensing receptor modulators |
| IN1672MUN2014 IN2014MN01672A (en) | 2012-02-24 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01672A true IN2014MN01672A (en) | 2015-05-29 |
Family
ID=54261188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1672MUN2014 IN2014MN01672A (en) | 2012-02-24 | 2013-02-22 |
Country Status (44)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102041154B1 (en) * | 2012-02-24 | 2019-11-07 | 루핀 리미티드 | Substituted chroman compounds as calcium sensing receptor modulators |
| CN104583177B (en) * | 2012-08-27 | 2016-09-07 | 卢平亚特兰蒂斯控股有限公司 | Aryl alkyl amines as calcium-sensing receptor regulator |
| TW201602062A (en) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | Substituted biphenyl compounds as calcium sensing receptor modulators |
| CA2920818A1 (en) | 2013-08-28 | 2015-03-05 | Lupin Limited | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| MX2022006087A (en) * | 2019-11-19 | 2022-08-11 | Lupin Ltd | Process for preparing chroman compounds. |
| EP4081210A1 (en) | 2019-12-27 | 2022-11-02 | Lupin Limited | Pharmaceutical composition of casr modulators and methods and uses thereof |
| JP7798770B2 (en) * | 2020-01-17 | 2026-01-14 | ルピン・リミテッド | Methods, processes and intermediates for preparing chroman compounds |
| WO2025255092A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3063585D1 (en) * | 1979-05-19 | 1983-07-07 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| FR2809396B1 (en) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | NOVEL MOLECULES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION |
| FR2812875B1 (en) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | NOVEL DIAMINES HAVING CASR MODULATING ACTIVITY AND THEIR METHOD OF PREPARATION |
| US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
| WO2004106280A1 (en) | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | CaSR ANTAGONIST |
| JP4573133B2 (en) | 2005-05-19 | 2010-11-04 | アステラス製薬株式会社 | Pyrrolidine derivative or its salt |
| TW200815388A (en) | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| EP2079739A2 (en) | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| EP2079525A1 (en) * | 2006-10-26 | 2009-07-22 | Amgen Inc. | Calcium receptor modulating agents |
| US8153658B2 (en) | 2006-11-16 | 2012-04-10 | Astellas Pharma, Inc. | Piperidine derivative or salt thereof |
| ES2476391T3 (en) * | 2007-10-15 | 2014-07-14 | Amgen Inc. | Calcium receptor modulating agents |
| CN101970394B (en) | 2007-11-23 | 2015-05-27 | 利奥制药有限公司 | Novel cyclic hydrocarbon compounds for the treatment of diseases |
| EP2345636B1 (en) | 2008-10-03 | 2016-03-30 | Ajinomoto Co., Inc. | Casr agonist |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| JP2012528086A (en) | 2009-05-27 | 2012-11-12 | レオ ファーマ アクティーゼルスカブ | Novel calcium-sensing receptor modulatory compound and pharmaceutical use thereof |
| WO2010150837A1 (en) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | Indoline derivative |
| RU2013128968A (en) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | COMPOUNDS ACTIVE AGAINST THE CALCIUM-SENSITIVE RECEPTOR |
| US20130267516A1 (en) | 2010-11-26 | 2013-10-10 | Leo Pharma A/S | Substituted cyclopentyl-azines as casr-active compounds |
| US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| CA2828415A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| WO2012127385A1 (en) * | 2011-03-18 | 2012-09-27 | Lupin Limited | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
| KR102041154B1 (en) * | 2012-02-24 | 2019-11-07 | 루핀 리미티드 | Substituted chroman compounds as calcium sensing receptor modulators |
-
2013
- 2013-02-22 KR KR1020147025242A patent/KR102041154B1/en active Active
- 2013-02-22 HU HUE13712928A patent/HUE046172T2/en unknown
- 2013-02-22 AP AP2014007919A patent/AP2014007919A0/en unknown
- 2013-02-22 MX MX2014010139A patent/MX355670B/en active IP Right Grant
- 2013-02-22 PL PL13712928T patent/PL2817299T3/en unknown
- 2013-02-22 HR HRP20191606 patent/HRP20191606T1/en unknown
- 2013-02-22 ES ES13712928T patent/ES2743492T3/en active Active
- 2013-02-22 BR BR112014021133-7A patent/BR112014021133B1/en active IP Right Grant
- 2013-02-22 NZ NZ628627A patent/NZ628627A/en unknown
- 2013-02-22 GE GEAP201813579A patent/GEAP201813579A/en unknown
- 2013-02-22 GE GEAP201313579A patent/GEP20186911B/en unknown
- 2013-02-22 PT PT13712928T patent/PT2817299T/en unknown
- 2013-02-22 CN CN201380021510.0A patent/CN104350047B/en active Active
- 2013-02-22 EP EP13712928.4A patent/EP2817299B1/en active Active
- 2013-02-22 EA EA201491582A patent/EA026940B9/en unknown
- 2013-02-22 CU CUP2014000103A patent/CU24325B1/en unknown
- 2013-02-22 SI SI201331561T patent/SI2817299T1/en unknown
- 2013-02-22 RS RSP20191101 patent/RS59172B1/en unknown
- 2013-02-22 CA CA2864332A patent/CA2864332C/en active Active
- 2013-02-22 JP JP2014558258A patent/JP6114316B2/en active Active
- 2013-02-22 WO PCT/IB2013/051445 patent/WO2013124828A1/en not_active Ceased
- 2013-02-22 IN IN1672MUN2014 patent/IN2014MN01672A/en unknown
- 2013-02-22 SG SG11201405117SA patent/SG11201405117SA/en unknown
- 2013-02-22 UA UAA201410409A patent/UA112679C2/en unknown
- 2013-02-22 DK DK13712928.4T patent/DK2817299T3/en active
- 2013-02-22 US US14/380,632 patent/US9163001B2/en active Active
- 2013-02-22 AU AU2013223715A patent/AU2013223715B2/en active Active
- 2013-02-22 MY MYPI2014702272A patent/MY171374A/en unknown
- 2013-02-22 LT LTEP13712928.4T patent/LT2817299T/en unknown
- 2013-02-22 SM SM20190506T patent/SMT201900506T1/en unknown
- 2013-02-22 PE PE2014001297A patent/PE20142281A1/en active IP Right Grant
- 2013-02-23 TW TW102106358A patent/TWI617549B/en not_active IP Right Cessation
- 2013-02-25 AR ARP130100556A patent/AR090135A1/en active IP Right Grant
-
2014
- 2014-08-14 TN TNP2014000352A patent/TN2014000352A1/en unknown
- 2014-08-15 ZA ZA2014/05990A patent/ZA201405990B/en unknown
- 2014-08-20 CL CL2014002218A patent/CL2014002218A1/en unknown
- 2014-08-20 PH PH12014501891A patent/PH12014501891B1/en unknown
- 2014-08-21 NI NI201400094A patent/NI201400094A/en unknown
- 2014-08-21 DO DO2014000193A patent/DOP2014000193A/en unknown
- 2014-08-21 IL IL234252A patent/IL234252A/en active IP Right Grant
- 2014-08-22 GT GT201400179A patent/GT201400179A/en unknown
- 2014-09-10 MA MA37344A patent/MA35937B1/en unknown
- 2014-09-17 CR CR20140424A patent/CR20140424A/en unknown
- 2014-09-23 CO CO14210706A patent/CO7160018A2/en unknown
-
2015
- 2015-09-01 US US14/842,141 patent/US9598391B2/en active Active
-
2017
- 2017-01-26 US US15/416,684 patent/US9987249B2/en active Active
-
2019
- 2019-09-10 CY CY20191100947T patent/CY1122017T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01672A (en) | ||
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| EA201270815A1 (en) | ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| MX2015011132A (en) | Polycyclic estrogen receptor modulators and uses thereof. | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12013501899A1 (en) | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators | |
| EA201270720A1 (en) | ANDROGEN RECEPTOR MODULATORS AND THEIR APPLICATION | |
| MX2013012896A (en) | NEW COMPOUNDS AS PROTEIN KINASE MODULATORS. | |
| MX2015005891A (en) | Polymorphic forms of suvoroxant. | |
| PH12014501079A1 (en) | 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions | |
| MX361349B (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions. | |
| MX2016004540A (en) | Thiazolopyrimidinones as modulators of nmda receptor activity. | |
| EA201400623A1 (en) | NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR | |
| WO2014068586A3 (en) | Solid oral compositions of tolvaptan | |
| IN2015MN00421A (en) | ||
| MX2013013436A (en) | Substituted indole derivatives for the treatment of immunological disorders. | |
| PH12014500934A1 (en) | Nicotinic receptor non-competitive modulators | |
| WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |